TACI: A novel immune checkpoint in Chronic Lymphocytic Leukemia

TACI：慢性淋巴细胞白血病的新型免疫检查点

• 批准号: nhmrc : 1143687
• 负责人: Dr Constantine Tam
• 金额: $ 59.13万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/taci-novel-immune-lymphocytic-leukemia/1320013
• 关键词: TACI; novel; immune; checkpoint; Chronic

Chronic Lymphocytic Leukemia (CLL) is a very common blood cancer. CLL cells actively shut down immune defenses in patients. Moreover, current as well as emerging more targeted therapies suppress immunity and over a quarter of patients will die from an infection despite a good response to cancer treatments. Our laboratory has gained new understanding in the mechanism of action of a new treatment for CLL called Ibrutinib. This information allows us to design improved treatment options for CLL.

慢性淋巴细胞白血病（CLL）是一种非常常见的血液癌症。CLL细胞主动关闭患者的免疫防御。此外，目前以及新兴的更有针对性的治疗抑制免疫力，超过四分之一的患者将死于感染，尽管对癌症治疗有良好的反应。我们的实验室已经获得了新的理解，在一个新的治疗慢性淋巴细胞白血病的作用机制称为伊曲替尼。这些信息使我们能够为CLL设计更好的治疗方案。